Runda Medical(603108)

Search documents
润达医疗:可转债转股结果暨股份变动的公告
2024-10-08 09:41
| 证券代码:603108 | 证券简称:润达医疗 | 公告编号:临 | 2024-047 | | --- | --- | --- | --- | | 转债代码:113588 | 转债简称:润达转债 | | | 上海润达医疗科技股份有限公司 重要内容提示: 一、 可转债发行上市概况 (一)经中国证券监督管理委员会证监许可[2020]586 号文核准,上海润达 医疗科技股份有限公司于 2020 年 6 月 17 日公开发行了 5,500,000 张(550,000 手)可转换公司债券,每张面值 100 元,发行总额 55,000 万元,发行期限 6 年, 票面利率分别为:第一年 0.3%、第二年 0.6%、第三年 1.0%、第四年 1.5%、第 五年 1.8%、第六年 2.0%。 (二)经上海证券交易所"[2020]185 号"自律监管决定书同意,公司 55,000 万元可转换公司债券于 2020 年 7 月 13 日起在上海证券交易所上市交易,债券简 称"润达转债",债券代码"113588"。 累计转股情况:截至 2024 年 9 月 30 日,累计人民币 253,400,000 元的"润 达转债"转换成公司 ...
润达医疗:关于控股股东权益变动超过1%的提示性公告
2024-10-08 09:41
| 证券代码:603108 | 证券简称:润达医疗 | 公告编号:临 | 2024-048 | | --- | --- | --- | --- | | 转债代码:113588 | 转债简称:润达转债 | | | 上海润达医疗科技股份有限公司 关于控股股东权益变动超过 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 上海润达医疗科技股份有限公司(以下简称"公司"或"润达医疗")收到 控股股东杭州市拱墅区国有投资集团有限公司(以下简称"拱墅国投")发来的 告知函,因2024年9月18日至2024年9月30日期间,拱墅国投接受的表决权委托股 份减持,拱墅国投的权益发生变化,现将有关情况公告如下: 本次权益变动后,公司控股股东拱墅国投持有的公司股份数量及比例不 变,合计能够行使的公司有表决权股份数量由 156,353,406 股变动至 148,858,406 股,比例由 26.11%变动至 24.86%。 本次权益变动是由于拱墅国投能够行使的公司有表决权股份数量减少, 拱墅国投未减持公司股份。 本次权 ...
润达医疗:上海润达医疗科技股份有限公司2024年半年度业绩说明会召开情况
2024-09-19 08:45
证券代码:603108 证券简称:润达医疗 转债代码:113588 转债简称:润达转债 上海润达医疗科技股份有限公司 关于 2024 年半年度业绩说明会召开情况 一、本次业绩说明会召开情况 上海润达医疗科技股份有限公司(以下简称"公司")2024 年半年度业绩说 明会于 2024 年 9 月 19 日 10:00-11:00 通过上海证券报•中国证券网路演中心 (https://roadshow.cnstock.com)以网络文字互动形式举行。公司董事长、董事会 秘书张诚栩先生,副董事长、总经理刘辉先生,独立董事何嘉先生,财务总监廖 上林先生就公司业绩等情况与投资者进行了交流沟通。 二、投资者提出的主要问题及公司回复情况 问题 1:请问公司各业务板块经营情况如何? 回答:您好,公司主营业务立足于院内检测市场,上半年公司核心服务型业 务(集约化业务/区域检验中心业务)及工业板块业务保持了较稳定的发展。 上半年,公司集约化业务/区域检验中心业务实现营业收入 12.35 亿元,较上 年同期基本持平,主要是受到医疗政策环境影响,医疗机构客户增长受到一定影 响,同时,公司终止了部分回款期长的集约化客户业务。后续随着医疗 ...
润达医疗:关于控股股东权益变动超过1%的提示性公告
2024-09-18 10:38
上海润达医疗科技股份有限公司(以下简称"公司"或"润达医疗")收到 控股股东杭州市拱墅区国有投资集团有限公司(以下简称"拱墅国投")发来的 告知函,因2023年8月2日至2024年9月13日期间,公司可转债转股导致权益比例 被动稀释及拱墅国投接受的表决权委托股份减持,拱墅国投的权益发生变化,现 将有关情况公告如下: | 信息披露 义务人基 | 名称 住所 | 杭州市拱墅区国有投资集团有限公司 浙江省杭州市拱墅区绍兴路 号国投大厦 | | | 398 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 1508 室 | | 本信息 | 权益变动时间 | 年 年 月 2023 9 13 | 8 | 月 2 | 日~2024 | | 日 | | 权益变动 | 变动方式 | 变动股数 变动日期 | | 股份种类 | | | 变动比例 | | 明细 | | | | | | (股) | | | 证券代码:603108 | 证券简称:润达医疗 | 公告编号:临 | 2024-045 | | --- | --- | --- | --- ...
润达医疗:“2B+2C”大模型同步发布,多场景实现商业应用
申万宏源· 2024-09-12 01:41
Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The company launched a medical large model named "CDx" on September 10, which aims to enhance the healthcare industry through various applications [3] - The model leverages a robust data foundation with nearly 100,000 data annotations, transforming clinical text records into fully structured data [3] - The "2B+2C" model includes solutions for hospitals and consumers, providing functionalities such as clinical assistance, medical record generation, and health management [3] - The company has initiated multiple applications across different scenarios, including health management AI robots and smart pharmacy upgrades [3] - The medical large model is positioned to address the imbalance in healthcare resources, enhancing decision-making for doctors and improving the diagnostic capabilities of lower-tier hospitals [3] Financial Summary - The company's total revenue for 2023 is projected at 9,147 million, with a slight decline expected in 2024 [4][6] - The net profit attributable to the parent company is forecasted to be 360 million in 2024, increasing to 610 million by 2026 [4][6] - The earnings per share are expected to rise from 0.60 in 2024 to 1.02 in 2026 [4][6] - The company’s gross margin is anticipated to improve gradually from 27.6% in 2024 to 28.5% in 2026 [4][6]
润达医疗:关于召开2024年半年度业绩说明会的公告
2024-09-09 07:37
| 证券代码:603108 | 证券简称:润达医疗 | 公告编号:临 | 2024-044 | | --- | --- | --- | --- | | 转债代码:113588 | 转债简称:润达转债 | | | 上海润达医疗科技股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: (https://roadshow.cnstock.com) 会议召开方式:网络文字互动 一、 说明会类型 本次投资者说明会以网络文字互动方式召开,公司将针对 2024 年半年度经 营成果及财务状况与投资者进行互动交流和沟通,在信息披露允许的范围内就投 资者普遍关注的问题进行回答。 问题征集方式:投资者可于 2024 年 9 月 17 日(星期二)下午 16:00 前将需要 了解的情况和关注的问题通过电子邮件的形式发送至公司邮箱 (board@rundamedical.com),公司将在说明会上就投资者普遍关注的问题进行 回答。 上海润达医疗科技股份有限公司(以下简称"公司")已于 ...
润达医疗:关于上月为子公司担保的进展情况公告
2024-09-02 07:35
| 证券代码:603108 | 证券简称:润达医疗 | 公告编号:临 | 2024-043 | | --- | --- | --- | --- | | 转债代码:113588 | 转债简称:润达转债 | | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、担保情况概述 (一)为支持上海润达医疗科技股份有限公司(以下简称"公司")全资 及控股子公司的发展,解决其流动资金短缺问题,经公司董事会及 2023 年 度股东大会审议通过:自 2024 年 5 月 23 日至 2024 年度股东大会召开之日 期间,为公司全资及控股子公司向(类)金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保,控股子公司其他股东提供 对等担保或为公司提供足额反担保,公司实际承担出资比例对应的担保金额。 被担保人名称:两家全资子公司:杭州润达、惠中医疗;五家控股子公 司:合肥润达、云南康泰、上海润医、武汉优科、苏州润达。被担保人 非上市公司 ...
润达医疗(603108) - 2024 Q2 - 季度财报
2024-08-28 07:47
Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a year-on-year increase of 15%[8]. - The net profit attributable to shareholders was RMB 80 million, up 20% compared to the same period last year[8]. - The company's operating revenue for the first half of 2024 was approximately ¥4.14 billion, a decrease of 8.54% compared to the same period last year[13]. - Net profit attributable to shareholders decreased by 47.82% year-on-year, amounting to approximately ¥91.31 million[13]. - Basic earnings per share dropped by 50.00% to ¥0.15, while diluted earnings per share also decreased by the same percentage[14]. - The net cash flow from operating activities increased significantly by 503.28%, reaching approximately ¥86.89 million[13]. - The company achieved total operating revenue of 4.135 billion RMB, a decrease of 8.54% compared to the same period last year, primarily due to the impact of medical policy environment on client development[45]. - The net profit attributable to the parent company was 91.31 million RMB, down 47.82% year-on-year, largely due to the decline in operating revenue and increased credit impairment losses[45]. - The company reported a significant increase of 90.33% in other current assets, totaling approximately ¥54.78 million[60]. - The company reported a net profit after deducting non-recurring gains and losses decreased by 49.51% to approximately 79.19 million RMB[104]. Market Strategy and Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[8]. - New product launches are expected to contribute an additional RMB 100 million in revenue for the second half of 2024[8]. - The company anticipates that future healthcare policies will drive medical institutions to focus more on cost reduction and efficiency improvement, increasing demand for comprehensive service capabilities[18]. - The company aims to reduce operational costs and improve efficiency through centralized procurement of materials and comprehensive laboratory management services[24]. - The company is focused on optimizing laboratory operations through customized value-added services, including quality control management and clinical education training[38]. Research and Development - The company is investing RMB 50 million in R&D for new technologies, focusing on point-of-care testing systems[8]. - The company has committed to enhancing its R&D capabilities, focusing on diverse and specialized product lines in IVD manufacturing to meet clinical needs[23]. - The company launched a new generation of HbA1c analyzers, MQ-3000, aimed at enhancing diabetes diagnosis capabilities in grassroots medical institutions[41]. - Research and development expenses decreased to approximately ¥56.53 million from ¥65.94 million, reflecting a reduction of 14.5%[120]. Operational Efficiency - The company has established over 2000 testing projects, including high-end diagnostic services such as molecular diagnostics and remote pathology, to meet the outsourcing needs of centralized clients and regional testing centers[22]. - The company is focused on digital transformation in laboratory management, developing various digital information products to enhance operational efficiency and quality control[25]. - The company has integrated a strong service network across various regions, ensuring timely and efficient delivery of IVD products and services[36]. - The company emphasizes the importance of specialized technical support and management services to help laboratories enhance diagnostic capabilities and operational efficiency[31]. Financial Position and Assets - The total assets at the end of the reporting period amounted to ¥14.48 billion, with cash and cash equivalents of ¥1.19 billion, representing 8.18% of total assets[60]. - Accounts receivable stood at approximately ¥5.51 billion, accounting for 38.03% of total assets, showing a slight decrease of 0.47% year-on-year[60]. - The company reported a significant increase in short-term borrowings, which rose to ¥5,108,577,489.00 from ¥4,711,694,456.01, reflecting an increase of approximately 8.36%[114]. - The company's total equity rose to CNY 2,866,516,558.01, compared to CNY 2,826,904,220.66, reflecting a growth of 1.40%[118]. Corporate Governance and Compliance - The board of directors has confirmed the authenticity and completeness of the financial report[2]. - There are no significant non-operational fund occupations by controlling shareholders reported[2]. - The company has not faced any violations in decision-making procedures regarding external guarantees[2]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[77]. Environmental and Social Responsibility - The company promotes energy conservation and waste reduction initiatives among employees, including a paperless office policy and recycling programs[73]. - The company is actively engaged in social responsibility initiatives, integrating energy-saving measures into daily operations[74]. - The company has established a hazardous waste management system and collaborates with qualified waste disposal firms to ensure safe handling of hazardous materials[72]. Shareholder Information - The total share capital of the company was 598,855,596 shares, with an increase of 1,651,784 shares during the reporting period due to the conversion of bonds[89]. - The largest shareholder, Hangzhou Gongshu District State-owned Investment Group Co., Ltd., held 116 million shares, accounting for 19.37% of the total shares[91]. - The company has confirmed that there are no significant non-operating fund occupations by major shareholders or related parties during the reporting period[77]. Debt and Financing - The company's interest-bearing debt decreased from 30.21 billion RMB at the beginning of the reporting period to 30.13 billion RMB at the end, representing a year-on-year change of -7.86%[98]. - The total interest-bearing debt amounts to 71.17 billion RMB, with 33.47 billion RMB due within 6 months[101]. - The company has not issued any new shares to strategic investors or general legal entities during the reporting period[93]. Accounting and Financial Reporting - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[143]. - The company’s financial statements are prepared based on the going concern assumption, indicating a positive outlook for the next 12 months[142]. - The company recognizes revenue when control of goods is transferred to customers, typically upon receipt of the signed delivery note[196].
润达医疗:监事会决议公告
2024-08-28 07:44
| 证券代码:603108 | 证券简称:润达医疗 | 公告编号:临 | 2024-041 | | --- | --- | --- | --- | | 转债代码:113588 | 转债简称:润达转债 | | | 上海润达医疗科技股份有限公司 监事会决议公告 本次监事会经过了适当的通知程序,会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定,会议及通过的决议合 法有效。 二、监事会会议审议情况 (一)审议通过了《关于审议公司2024年半年度报告及摘要的议案》。 监事会根据《公司法》、《证券法》、《公开发行证券的公司信息披露内容与格 式准则第 3 号—半年度报告的内容与格式》等有关规定,对公司 2024 年半年度 报告进行了认真严格的审核,一致认为: 1、公司《2024 年半年度报告》编制和审议程序符合法律、法规、《公司章 程》和公司内部管理制度的规定; 2、半年度报告的内容和格式符合中国证监会和上海证券交易所的各项规定, 所包含的信息能从各个方面真实地反映出公司 2024 年上半年的经营管理和财务 状况; 3、未发现参与半年度报告编制和审议的人员有违反保密规定的行为; 本公司 ...